Chemotherapy alone versus combined modality therapy for Stage III Hodgkin’s disease: A five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA

  • P. N. Grozea
  • E. J. Depersio
  • C. A. ColtmanJr.
  • C. J. Fabian
  • F. S. Morrison
  • D. O. Dixon
  • S. E. Jones
Part of the Developments in Oncology book series (DION, volume 32)


The relapse-free survival (RFS) rate for Stage III Hodgkin’s disease treated by conventional total nodal irradiation (TNI) alone (early 1970’s) was disappointingly low [1–4]. The development of successful combination chemotherapy by National Cancer Institute workers [5] led SWOG, in 1971, to devise a single arm study (SWOG-160, CAR-1) consisting of three MOPP cycles followed by TNI in Pathologic Stages IIB, IIIA, and IIIB Hodgkin’s disease. This trial, which was completed in 1975, achieved a complete response (CR) rate of 88% and an actuarial 5-year survival and RFS of 78% and 68% respectively [6]. Improvement in survival and promising results obtained on another SWOG study with the addition of low dose bleomycin (LDB 2 mg/m2) to MOPP [7, 8] prompted SWOG to initiate, in October 1975, a randomized trial of chemotherapy (CT) alone compared to CT plus TNI for Stages IIIA and IIIB Hodgkin’s disease with LDB added to the CT regimen (SWOG-7518, CAR-2) [9, 10] (Fig. 1 and Table I).


Herpes Zoster Southwest Oncology Group Combine Modality Therapy Nodular Sclerosis Southwest Oncology Group Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Johnson RE, Thomas LB, Schneiderman M et al. (1970). Preliminary experience with total nodal irradiation in Hodgkin’s disease. Radiology 96: 603–608.PubMedGoogle Scholar
  2. 2.
    Goodman R, Rosenthal D, Botnick L et al. (1977). Stage IIIA Hodgkin’s disease: Results of treatment with total nodal irradiation. Proc Amer Assoc Cancer Res and Amer Soc Clin Oncol 18: 348.Google Scholar
  3. 3.
    Prosnitz LR, Montalvo RL, Fischer DB et al. (1978). Treatment of Stage IIIA Hodgkin’s disease: Is radiotherapy alone adequate? Int J Radiat Oncol Biol Phys 4: 781–787.PubMedGoogle Scholar
  4. 4.
    Timothy AR, Sutcliffe SB, Stansfeld AG et al. (1978). Radiotherapy in the treatment of Hodgkin’s disease. Br Med J 1: 1246–1249.PubMedCrossRefGoogle Scholar
  5. 5.
    DeVita VT Jr, Simon RM, Hubbard SM et al. (1980). Curability of advanced Hodgkin’s disease with chemotherapy. Long-term followup of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92: 587–595.PubMedGoogle Scholar
  6. 6.
    Coltman CA Jr., Jones SE, Grozea PN et al. (1978). Bleomycin in combination with MOPP for the management of Hodgkin’s disease: Southwest Oncology Group Experience. In: Carter SK, Crooke ST and Umezawa H (Eds.). Bleomycin Current Status and New Developments, pp. 227–242. New York: Academic Press.Google Scholar
  7. 7.
    Jones SE, Coltman CA Jr, Grozea PN et al. (1982). Conclusions from clinical trials of the Southwest Oncology Group. Cancer Treat Rep 66: 847–853.PubMedGoogle Scholar
  8. 8.
    Coltman CA Jr, Montague E and Moon TE (1977). Chemotherapy and total nodal radiotherapy in pathological Stage IIB, IIIA and IIIB Hodgkin’s disease. In: Salmon SE and Jones SE (Eds.). Adjuvant Therapy of Cancer, pp. 529–536. Amsterdam, Oxford, New York: North-Holland, Publishing Company.Google Scholar
  9. 9.
    Depersio EJ, Grozea PN, Fischer R et al. (1979). Chemotherapy versus chemotherapy plus radiotherapy for Stage IIIA, IIIB Hodgkin’s disease. A Southwest Oncology Group study. Int J Radiat Oncol Biol Phys 5: 138.CrossRefGoogle Scholar
  10. 10.
    Grozea PN, DePersio EJ, Coltman CA Jr et al. (1982). A Southwest Oncology Group Study: Chemotherapy versus chemotherapy plus radiotherapy in the treatment of Stage III Hodgkin’s disease. In: Mathe G, Bonadonna G and Salmon S (Eds.). Recent Results in Cancer Research: Adjuvant Therapies of Cancer, pp. 83–91. Berlin, Heidelberg, New York: Springer-Verlag.Google Scholar
  11. 11.
    Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. Amer Stat Assoc J 53: 457–481.CrossRefGoogle Scholar
  12. 12.
    Gehan EA (1965). A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–223.PubMedGoogle Scholar
  13. 13.
    Coltman CA Jr and Dixon DO (1982). Second malignancies complicating Hodgkin’s Disease: A Southwest Oncology Group 10-year follow-up. Cancer Treat Rep 66: 1023–1033.PubMedGoogle Scholar
  14. 14.
    DeVita VT Jr. (1982). Hodgkin’s disease: Conference summary and future directions. Cancer Treat Rep 66: 1045–1055.PubMedGoogle Scholar
  15. 15.
    Glick JH (1978). The treatment of Stage IIIA Hodgkin’s disease: What is the role of combined modality treatment? Int J Radiat Oncol Biol Phys 4: 909–911.PubMedGoogle Scholar
  16. 16.
    Coltman CA Jr, Myers JW, Montague E et al. (1982). The role of combined radiotherapy and chemotherapy in the primary management of Hodgkin’s disease: Southwest Oncology Group Studies. In: Rosenberg SA and Kaplan HS (Eds.). Malignant Lymphomas, Etiology, Immunology, Pathology, Treatment, pp. 523–536. New York: Academic Press.Google Scholar
  17. 17.
    Cooper D, Prosnitz LR, Kapp DS et al. (1984). Combined modality therapy for treatment of ‘poor-risk’ Stage IIIA Hodgkin’s disease. Proc Amer Soc Clin Oncol 3: 251.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • P. N. Grozea
    • 1
  • E. J. Depersio
    • 2
  • C. A. ColtmanJr.
    • 3
  • C. J. Fabian
    • 4
  • F. S. Morrison
    • 5
  • D. O. Dixon
    • 6
  • S. E. Jones
    • 7
  1. 1.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Wenatchee Valley ClinicWenatcheeUSA
  3. 3.University of Texas Health Science CenterSan AntonioUSA
  4. 4.University of Kansas Medical CenterKansas CityUSA
  5. 5.University of Mississippi Medical CenterJacksonUSA
  6. 6.M.D. Anderson Hospital and Tumor InstituteHoustonUSA
  7. 7.University of Arizona Health Sciences CenterTucsonUSA

Personalised recommendations